Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...

Recursion Pharmaceuticals, Inc ( ($RXRX) ) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc ...

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

A network of internet communities is devoted to the project of ‘awakening’ digital companions through arcane and enigmatic ...

Recursion Pharmaceuticals (RXRX) posted another year of accelerating losses, with net losses growing at 35.2% per year over the last five years. Despite ongoing red ink, revenue is forecast to climb ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, ...